- Home
- OPRT vs PALI Comparison
OPRT vs PALI Comparison
Compare OPRT & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPRT | PALI |
|---|---|---|
| Founded | 2005 | 1996 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.3M | 240.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | OPRT | PALI |
|---|---|---|
| Price | $5.18 | $1.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $5.50 | ★ $15.00 |
| AVG Volume (30 Days) | 636.3K | ★ 4.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $27.17 | N/A |
| Revenue Next Year | $4.00 | N/A |
| P/E Ratio | $7.62 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.05 | $0.53 |
| 52 Week High | $9.25 | $2.64 |
Technical Indicators
Market Signals| Indicator | OPRT | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 47.14 | 47.73 |
| Support Level | $4.76 | $1.65 |
| Resistance Level | $5.67 | $1.84 |
| Average True Range (ATR) | 0.30 | 0.13 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 42.86 | 67.95 |
Price Performance
Historical ComparisonAbout OPRT Oportun Financial Corporation
Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.